--(www.USEquityNews.com)-- 05/02/2008 - Healthcare industry alert provided by U.S. Equity News. TapImmune Inc. (OTC BB: TPIM) announces completion of initial testing on our bench made vaccine at AppTech. The company now has the necessary data to proceed with clinical grade vaccine stock production. Going forward, our work and development program includes phased manufacturing and production for both infectious disease adjuvant and cancer therapeutic vaccine candidates. These will culminate in toxicology studies and will coincide with pre-IND meeting preparation with the FDA and clinical protocols for our proposed phase 1 human studies. This milestone is predicated on the back of a year where we have seen the completion of the UBC assignment agreement finally effecting our acquisition of the core technologies we developed under the world-wide license agreement.
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported financial results for the three months ended March 31, 2008. The Company reported a net loss for the first quarter of approximately ($8.3 million), or ($0.10) per share, compared with a net loss of ($7.7 million), or ($0.09) per share, for the same period last year. The Company did not report any revenues for the first quarter 2008. As of March 31, 2008, the Company had cash and short-term investments of approximately $44 million.
Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that Acorda management will present a corporate overview at the upcoming Baird 2008 Growth Stock Conference at the Four Seasons Hotel in Chicago, IL and at the Bank of America 2008 Health Care Conference at the Four Seasons Hotel in Las Vegas, NV. The Baird 2008 Growth Stock Conference presentation will take place on Tuesday, May 13, 2008 at 3:40 p.m. CT. A live webcast of the presentation can be accessed under "Calendar of Events" in the Acorda Investor Relations section of the website at www.acorda.com. The Bank of America 2008 Health Care Conference presentation will take place on Thursday, May 15, 2008 at 9:50 a.m. PT. A live webcast of the presentation can be accessed under "Calendar of Events" in the Acorda Investor Relations section of the website at www.acorda.com.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Leerink Swann Cancer Roundtable Conference titled Conquering Cancer with Novel Therapeutics, to be held at The Grand Hyatt in New York, New York on Friday, May 9, 2008. Timothy P. Clackson, Ph.D., senior vice president and chief scientific officer at ARIAD, will provide an overview of the Company and its progress in key programs in a corporate presentation at 10:00 a.m. (ET). Dr. Clackson also will participate in a panel discussion titled, "Novel Targeted Agents for Cancer - What Target and Which Pathway?" at 8:35 a.m. (ET).
About U.S. Equity News
U.S. Equity News provides information, resources and news services for investors of small-cap, micro-cap and emerging companies. U.S. Equity News distributes RSS news feeds and a free subscription-based newsletter available through its website at www.usequitynews.com.
U.S. Equity News is a financial news distribution service by Equity Solutions, Inc. (www.equityirsolutions.com) that provides a platform for public companies to disseminate important news to key Wall Street interest such as shareholders and new investors. Equity Solutions, Inc. can assist by providing an effective increase in the awareness of a public company's news, development and corporate story through its proprietary network and its financial portal. U.S. Equity News and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.USEquityNews.com.
